Ultragenyx Pharmaceutical Inc.RARE
NASDAQ • Healthcare
$26.41
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
-2.4% YoY
Gross Margin
77.9%
Health Score
3/10
D/E Ratio
-15.95
Confidence
LOW
Business Snapshot
Ultragenyx Pharmaceutical is a biotechnology company focused on developing therapies for rare and serious diseases. Its primary revenue-generating products come from approved treatments in the rare disease space, although specific segment breakdowns are not provided. The company operates in a competitive rare disease drug market, competing with other biotechs and large pharma. Financially, it has trailing twelve-month revenue of $669.43M but remains deeply unprofitable with a net loss of -$609.36M. A defining characteristic is its significant cash burn, with negative free cash flow of -$472M, requiring ongoing external capital to fund operations.
Financial Health
Gross margin is 77.9%, down from 86.0% in the prior year, indicating deteriorating pricing power or cost structure. Net margin is -91.0%, reflecting that the company loses nearly a dollar for every dollar of revenue...
Risk Assessment
- VALUATION — Price/sales of 3.89x and price/book of 15.22x are stretched for a company with -91% net margins and declining revenue.
- EARNINGS QUALITY — Only 1 of the last 4 quarters beat analyst estimates, reflecting low earnings predictability and poor guidance credibility.
- REVENUE DECELERATION — Revenue fell 34.3% sequentially versus a 2.4% year-over-year decline, indicating a severe recent slowdown.
- DEBT — Debt/equity of -15.95x is deeply negative, implying negative book equity and potential solvency concerns despite a healthy current ratio of 2.48x.
- 52-WEEK POSITION — The current price of $26.41 is 37.6% below the 52-week high of $42.37 and below the midpoint of the range ($30.33), suggesting persistent weakness.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- FCF / CASH BURN — Free cash flow is -$472M, reflecting heavy cash consumption with no offsetting free cash flow yield....